Stanford

Jeffrey Dunn, MD

Clinical Professor, Neurology & Neurological Sciences

NIH Biosketch available Online Curriculum Vitae available Online

CLINICAL OFFICE (PRIMARY)

- **Stanford Neuroscience Health Center**

  213 Quarry Rd

  MC 5957 Fl 2

  Palo Alto, CA 94304

  Tel (650) 736-4310 **Fax** (650) 725-7459

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

  Amy Singh - Administrative Associate

  Tel 650.736.4310

Bio

BIO

Jeffrey Dunn, MD serves as the Lily Sarafan Director of Neuroimmunology, Clinical Professor and Chief of Neuroimmunology within the Department of Neurology & Neurological Sciences at Stanford University. He specializes in the diagnosis, treatment and research of immune-mediated diseases of the central nervous system, including Multiple Sclerosis, transverse myelitis, and Neuromyelitis Optica. Dr. Dunn is regarded as among the foundational leaders in his field and is an elected Fellow of the American Academy of Neurology. He is the past Chair of the MS Section of the AAN. As Principal Investigator in more than 30 clinical research trials, Dr. Dunn has helped usher in new and improved immunotherapies for Multiple Sclerosis, including most recently the investigation of cellular immune therapies for MS. He is the creator and Principal Investigator of Project BIG (see www.projectbig.com), an interdisciplinary research collaborative with Stanford scientists to identify biomarkers and candidate therapeutic targets within the paradigm of precision medicine. These collaborations have yielded such pivotal discoveries as EBV viral molecular mimicry as a driver of MS pathogenesis, a discovery recognized by the American Association for the Advancement of Science as a runner-up Science Breakthrough of the Year in 2022; and a T lymphocyte subtype having a key role in modulating human autoimmunity. Dr. Dunn is a US patent holder for a marker of MS treatment response with co-inventors, and has authored or co-authored more than 50 peer-reviewed manuscripts and abstracts. Dr. Dunn has been recognized for excellence in clinical teaching, as a 13 time winner of the Neurology Clerkship student teaching award, the Lysia Forno Award recipient for excellence in Neurology resident teaching, and by Arthur Bloomfield Awards and the Henry J. Kaiser Family Foundation. In recognition of his dedication to the educational mission, his name is given to the eponymous Fishers-Dunn Prize, awarded annually to best medical student teaching among active Neurology residents. His formative contributions to medical education were recognized by the inaugural Oscar Salvatierra Award for exceptional service to Stanford medical students awarded by the Stanford University School of Medicine.

CLINICAL FOCUS

- Multiple Sclerosis
- Neuromyelitis Optica
- Transverse Myelitis
- Neuromuscular Medicine

ACADEMIC APPOINTMENTS

- Clinical Professor, Neurology & Neurological Sciences

ADMINISTRATIVE APPOINTMENTS

- Lily Sarafan Director of Neuroimmunology, Stanford University Department of Neurology, (2022- present)
- Chief, Division of Neuroimmunology, Department of Neurology & Neurological Sciences, (2009- present)
- Chair, Multiple Sclerosis Section; American Academy of Neurology, (2018-2020)
- Neurology Clerkship Director, Stanford University School of Medicine, (2008-2019)
- Board Member, National Medical Advisory Committee, National Multiple Sclerosis Society, (2018-2021)
- Fellowship Director, Clinical Neuroimmunology Fellowship Program; Stanford University, (2010-2017)

HONORS AND AWARDS

- Top Docs 2024, CastleConnolly.com (2024)
- Certificate of Special Congressional Recognition, US Congress (CA-04) (2023)
- Neurology Clerkship Teaching Award, Stanford University Neurology (2022-2023)
- Science Breakthrough of the Year, runner-up, American Association for the Advancement of Science (2022)
- Oscar Salvatierra Award for Exceptional Service to Medical Students & Stanford School of Medicine, Stanford University School of Medicine (2021)
- Neurology Clerkship Teaching Award, Stanford University Neurology (2019-2020)
- A. B. Baker National Teacher of the Year Recognition Award, American Academy of Neurology (2019)
- Healthcare Partner of the Year, National Multiple Sclerosis Society, NorCal (2019)
- Arthur L. Bloomfield Award in Recognition of Excellence in Teaching Clinical Medicine, Stanford University School of Medicine (2017)
- Special Commendation for outstanding care, research and contributions to the MS community, California State Senate (2016)
- Henry J. Kaiser Family Foundation Award for Excellence in Clinical Teaching, Stanford University School of Medicine (2013)
- Top Doctors: the top doctors in the US as nominated by their peers, Castle Connolly (2012-2023 inclusive)
- AUPN Neurology highest percentage National Recruitment Award, Association of University Professors of Neurology (2012, 2011)
- Excellence in Teaching Award, Stanford University School of Medicine (2011-2012)
- Arthur L. Bloomfield Award in Recognition of Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine (2011)
- Excellence in Teaching Award, Stanford University School of Medicine (2010-2011)
- Excellence in Teaching Award, Stanford University School of Medicine (2009-2010)
- Fellow, American Academy of Neurology (2008-present)
- Excellence in Neurology Clerkship Teaching Award, Stanford University Neurology (2008-2017 inclusive)
- Lysia K. Forno Award for Excellence in Teaching Neurology Residents, Stanford University Department of Neurology & Neurosciences (2008-2009)
- America's Top Rated Physicians, Guide to Top Doctors (1998-2007 inclusive)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Fellow, American Academy of Neurology (2007 - present)
- Member, International Society of Neuroimmunology (2022 - present)
- Member, Consortium of MS Centers (2008 - present)
- Member, San Francisco Neurological Society (2009 - present)

PROFESSIONAL EDUCATION

- Board Certification: Neurology, American Board of Psychiatry and Neurology (1994)
- Residency: University of Washington Medical Center (1993) WA
- Medical Education: Temple University School of Medicine (1989) PA
- B.A., Haverford College , French Literature (1983)
- +, Institut d'Études Françaises , Avignon, France (1982)

COMMUNITY AND INTERNATIONAL WORK

- Orphan Outreach, Nairobi, Kenya, Africa
- Editorial Board

PATENTS

- Jeffrey Edward Dunn, Ryan D. Schubert, Robert C. Axtell. "United States Patent 10,054,588 Marker for determination of patient responsiveness", Leland Stanford Junior University, Aug 21, 2018

LINKS

- http://neurology.stanford.edu: http://neurology.stanford.edu
- Video Story: https://stanfordhealthcare.org/stanford-health-care-now/why-i-got-into-medicine/why-medicine-jeffrey-dunn-md.html
- Get a Second Opinion: https://stanfordhealthcare.org/second-opinion/overview.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Translational research in the human application of emerging immunotherapies for neurological disease, focusing on Multiple Sclerosis, CIS, transverse myelitis and Neuromyelitis Optica (NMO). Collaborative research with Stanford and extramural scientific faculty to identify biomarkers of disease activity and treatment response in humans. Clinical trials to assess efficacy of emerging treatments for MS, CIS and NMO.

CLINICAL TRIALS

- A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis, Recruiting
- Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS), Recruiting
- Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers, Recruiting
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis, Not Recruiting

PROJECTS

- Project BIG - Stanford University and Sarafan ChEM-H

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Danwei Wu

Publications

PUBLICATIONS

- **Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.** *Blood advances*
  Nie, E. H., Su, Y. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W. K., Smith, M., Dahiya, S., Han, M. H., Dunn, J. E., Kipp, L. B., Miklos, D. B., Scott, et al
  2024

- **Epidemiological and Clinical Outcome Determinants of Post-COVID-19 Myelopathy**
  Sumera, J., Sarkar, T., McDonald, J., Sattarnezhad, N., Nie, E., Kipp, L., Dunn, J., Han, M., Joseph, Y., Tomczak, A., Lock, C.
  SAGE PUBLICATIONS LTD.2023: 719

- **Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Ad Hoc Analysis From the Open-Label Extension DAYBREAK Study**
  Coyle, P., Dunn, J., Kappos, L., Cheng, C., Thorpe, A., Morello, J., Silva, D., Filippi, M.
  SAGE PUBLICATIONS LTD.2023: 957-958

- **SARS-CoV-2 Vaccine Immune Response on Anti-Complement Therapy, Eculizumab**
  Sattarnezhad, N., Sumera, J., McDonald, J., Nie, E., Tomczak, A., Joseph, Y., Kalle, S., Sarkar, T., Kipp, L., Lock, C., Dunn, J. E., Han, M.
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) in conjunction with Allogeneic Bone Marrow Transplantation and Autoimmune Neutropenia: A study of two companion cases and institutional review of the MOGAD clinical phenotype spectrum**
  Nie, E., McDonald, J., Dunn, J., Han, M.
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results from Randomized Phase 2b Core and Extension Studies.** *Neurology*
  Freedman, M. S., Pozzilli, C., Havrdova, E. K., Lemle, A., Burcklen, M., Larbalestier, A., Hennessy, B., Sidorenko, T., Vaclavkova, A., Olsson, T.
  2022

- **Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL.** *Multiple sclerosis and related disorders*
  Gawde, S., Agasing, A., Bhatt, N., Toliver, M., Kumar, G., Massey, K., Nguyen, A., Mao-Draayer, Y., Macwana, S., DeJager, W., Guthridge, J. M., Pardo, G., Dunn, et al
  2022; 63: 103922

- **A case of MOG antibody disoorder with pontine involvement mimicking CLIPPERS and extensive transverse myelitis**
  Keroles, M., Stocksdale, B., Ng, J., Ahadi, S., Dunn, J.
  LIPPINCOTT WILLIAMS & WILKINS.2022

- **KIR+CD8+ T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19.** *Science (New York, N.Y.)*
  Li, J., Zaslavsky, M., Su, Y., Guo, J., Sikora, M. J., van Unen, V., Christophersen, A., Chiou, S., Chen, L., Li, J., Ji, X., Wilhelmy, J., McSween, et al
  2022: eabi9591

- **Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.** *Nature*
  Lanz, T. V., Brewer, R. C., Ho, P. P., Moon, J. S., Jude, K. M., Fernandez, D., Fernandes, R. A., Gomez, A. M., Nadj, G. S., Bartley, C. M., Schubert, R. D., Hawes, I. A., Vazquez, et al
  2022

- **Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.** *Neurology. Clinical practice*
  Hua, L. H., Obeidat, A. Z., Amezcua, L., Cohen, J. A., Costello, K., Dunn, J., Gelfand, J. M., Goldman, M. D., Hopkins, S., Jeffery, D., Krieger, S., Newsome, S. D., Shah, et al
  2021; 11 (4): 352-357

- **Defining the Neuroimmunology/Multiple Sclerosis Subspecialty: Surveys of Fellowship Training in the United States**
  Longbrake, E., Obeidat, A., Dunn, J., Sicotte, N., Hua, L.
  LIPPINCOTT WILLIAMS & WILKINS.2020

- **Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.** *Journal of neuroinflammation*
  Gilmore, W. n., Lund, B. T., Li, P. n., Levy, A. M., Kelland, E. E., Akbari, O. n., Groshen, S. n., Cen, S. Y., Pelletier, D. n., Weiner, L. P., Javed, A. n., Dunn, J. E., Traboulsee, et al

2020; 17 (1): 189

- **The North American Registry for Care and Research in Multiple Sclerosis**
  Rammohan, K. W., Li, D., Halper, J., Murphy, S., Patton, L., Berger, J., Carlson, A. M., Chinea, A., Cohan, S., Cross, A. H., Dunn, J., Fox, E. J., Gupta, et al
  SAGE PUBLICATIONS LTD.2019: 79–80

- **Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management** *OPEN FORUM INFECTIOUS DISEASES*
  Epstein, D. J., Dunn, J., Deresinski, S.
  2018; 5 (8)

- **Autoimmune Hepatitis During Treatment of Multiple Sclerosis with Alemtuzumab**
  Carlson, A., Bozinov, N., Kipp, L., Dunn, J., Lock, C.
  LIPPINCOTT WILLIAMS & WILKINS.2018

- **Ocrelizumab versus Interferon beta 1a in Relapsing Multiple Sclerosis** *New England Journal of Medicine*
  Hauser, S. L., OPERA Clinical Investigators , et al
  2017; 376 (3): 221-234

- **Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.** *Neurology*
  Giovannoni, G., Cohen, J. A., Coles, A. J., Hartung, H. P., Havrdova, E., Selmaj, K. W., Margolin, D. H., Lake, S. L., Kaup, S. M., Panzara, M. A., Compston, D. A.
  2016; 87 (19): 1985-1992

- **IFN-ß Treatment Requires B Cells for Efficacy in Neuroautoimmunity.** *Journal of immunology*
  Schubert, R. D., Hu, Y., Kumar, G., Szeto, S., Abraham, P., Winderl, J., Guthridge, J. M., Pardo, G., Dunn, J., Steinman, L., Axtell, R. C.
  2015; 194 (5): 2110-2116

- **MRI CHARACTERISTICS OF CNS DEMYELINATING DISEASE IN ETHNIC INDIAN PATIENTS**
  Hua, L. H., Lee, J., Dorfman, L., Dunn, J.
  SAGE PUBLICATIONS LTD.2014: 920

- **Disease-modifying therapies for nonrelapsing multiple sclerosis: Absence of evidence does not constitute evidence of absence.** *Neurology. Clinical practice*
  Dunn, J.
  2013; 3 (6): 515–18

- **Analysis of B Cell Subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy Reveals Modulation of CD19+CD24hiCD38hi Cells with Implications for the Diagnosis and Monitoring of MS**
  Schubert, R., Goodyear, A., Abraham, P., Dunn, C., Steinman, L., Dunn, J., Axtell, R.
  LIPPINCOTT WILLIAMS & WILKINS.2013

- **Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis** *Annals of Neurology*
  Lublin, F., CombiRx Investigators
  2013; 73 (3): 327-340

- **Mobility Concerns in Multiple Sclerosis** *US Neurology*
  Lee, J., Dunn, J.
  2013; 9 (1): 17-23

- **Disease modifying therapies for non relapsing Multiple Sclerosis** *Neurol Clin Pract*
  Dunn, J.
  2013; December (3): 515-518

- **Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial** *LANCET*
  Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H., Havrdova, E., Selmaj, K. W., Weiner, H. L., Miller, T., Fisher, E., Sandbrink, et al
  2012; 380 (9856): 1829-1839

- **Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein** *MULTIPLE SCLEROSIS JOURNAL*

Herges, K., de Jong, B. A., Kolkowitz, I., Dunn, C., Mandelbaum, G., Ko, R. M., Maini, A., Han, M. H., Killestein, J., Polman, C., Goodyear, A. L., Dunn, J., Steinman, et al
2012; 18 (4): 398-408

- **Protective Effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin olidodendrocyte glycoprotein** *Multiple Sclerosis*
  Herges K, DeJong BA, Kolkowitz I, Dunn C, Mandelbaum G, Maini A, Han M, Killestein J, Polman C, Goodyear A, Dunn J, Steinman L, Axtell RC
  2012; 18 (4): 398-408

- **Alemtuzumab for patients with relapsing Multiple Sclerosis after disease modifying therapy: a randomized controlled Phase 3 trial.** *Lancet*
  A, C. J., CARE MS II, I.
  2012; Nov 24 (380): 1829-1839

- **Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis** *CURRENT MEDICAL RESEARCH AND OPINION*
  Dunn, J., Blight, A.
  2011; 27 (7): 1415-1423

- **Dalfampridine: A brief review of its Mechanism of Action and Efficacy as a treatment to improve walking in patients with Multiple Sclerosis** *Current Research Medical Opinion*
  Dunn J, Blight A
  2011; 27 (7): 1415-1423

- **Impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis** *EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH*
  Dunn, J.
  2010; 10 (4): 433-440

- **Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta** *LANCET NEUROLOGY*
  Wynn, D., Kaufman, M., Montalban, X., Vollmer, T., Simon, J., Elkins, J., O'Neill, G., Neyer, L., Sheridan, J., Wang, C., Fong, A., Rose, J. W.
  2010; 9 (4): 381-390

- **The impact of mobility impairment on the burden of caregiving in individuals with multiple sclerosis** *Expert Rev. Pharmacoeconomics Outcomes Res.*
  Dunn, J.
  2010; 10 (4): 433-440

- **Cytomegalovirus Infection with MRI Signal Abnormalities Affecting the Optic Nerves, Optic Chiasm, and Optic Tracts** *JOURNAL OF NEURO-OPHTHALMOLOGY*
  Pershing, S., Dunn, J., Khan, A., Liao, Y. J.
  2009; 29 (3): 223-226

- **CMV Optic Neuritis with Extensive Tracking along the Visual Pathway** *J Neuro-Ophthalmology*
  Pershing S, D. K.
  2009; 29 (3): 223-226

- **Glatiramer Acetate after Induction Therapy with Mitoxantrone in Relapsing Multiple Sclerosis** *Multiple Sclerosis*
  Vollmer T, P. B.
  2008; Apr 18

- **Tovaxin for Early Relapsing Multiple Sclerosis Phase 2b Placebo Controlled Trial of Autologous T cell vaccination in patients with CIS or RRMS** *Multiple Sclerosis*
  Fox, E., The TERMS Study Investigators
  2008; 14: S5-S27

- **Glatiramer Acetate after Mitoxantrone Induction improves MRI markers of lesion volume and permanent tissue injury in MS** *J Neurol*
  Arnold D., Campagnolo D., Panitch H., Bar-Or A., Dunn J, Freedman M., Gazda S.K., Vollmer T.
  2008; 255: 1473-1478

- **Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon beta Therapy; Week 24 data Phase II** *ECTRIMS*
  Montalban X, K. W.
  2007; 10/11/07: S18

- **Randomized, Double Blind, Dose Comparison Study of Glatiramer Acetate in Relapsing Remitting MS** *Neurology*
  Cohen JA, R. G.
  2007; 68 (12): 939-944
- **Safety and Tolerability of Glatiramer Acetate in Pediatric Patients with Relapsing Remitting Multiple Sclerosis** *ECTRIMS/ACTRIMS*
  Krupp L, Banwell B, Picone M, Dunn J, Weinstock-Guttman B, Pardo L.
  2005: abstract
- **Comprehensive Outpatient Management of Patients with Multiple Sclerosis** *RIMS MS Symposium*
  Odderson I, D.
  2001: abstract
- **Novantrone in the Treatment of Multiple Sclerosis** *Alliance News*
  Dunn Jeffrey, Kita M., Lucas S., Bowen J.,
  2001: 1-3
- **Clinical Advisory Committee Statement** *Health Care Connection*
  Bowen J., Dunn Jeffrey E., Kraft G.H., Ratley G., Shilling J., Smith C., Thompson L.
  1999; I (1): 1-2
- **Gingko Biloba in the Treatment of Alzheimer's Disease** *Alternative Medicine*
  Dunn Jeffrey E., Maidan R., Pallis J.
  1998; 1 (15): 1-2
- **Atherosclerotic Aortic Disease as a Source of Embolic Infarct** *Journal of Neurovascular Disease*
  Bursell John P.,Odderson I., Dunn Jeffrey E.
  1996; 1 (2): 35-38
- **INTRACEREBRAL BACILLARY ANGIOMATOSIS IN A PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS** *ANNALS OF INTERNAL MEDICINE*
  Spach, D. H., Panther, L. A., Thorning, D. R., Dunn, J. E., Plorde, J. J., MILLER, R. A.
  1992; 116 (9): 740-742
- **Intracerebral Bacillary Angiomatosis in a Patient Infected with HIV** *Annals of Internal Medicine*
  Spach, D., Panther L., Thorning D., Dunn Jeffrey E., Plorde J.L., Miller, R.
  1992; 116: 740-743

PRESENTATIONS

- The Utility of Magnetic Resonance Imaging in Multiple Sclerosis - Pan-Asian Committee for Treatment & Research in MS (11/6/2014)
- An Approach to Transverse Myelitis - Stanford University (10/31/2014)
- Treatment Decisions at the intersection of trials and practice - 6th Annual ECTRIMS-ACTRIMS (9/12/2014)
- Is Multiple Sclerosis not one disease but several? - Cleveland Clinic Foundation (6/27/2014)
- Multiple Sclerosis Highlights in the Field - American Academy of Neurology (4/30/2014)